Diabetes symptoms: What is the difference between Type 1 and Type 2 diabetes symptoms?

DIABETES affects about four million people in the UK, which means that 1 in every 16 people will have a type of the condition. But what is the difference between Type 1 and Type 2 diabetes symptoms?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

In conclusion, our case-control and meta-analysis studies did not indicate an association between the analyzed UCP2 polymorphisms and DKD.
Source: Genetics and Molecular Biology - Category: Genetics & Stem Cells Source Type: research
Managing insulin-dependent diabetes is no easy task. Most patients manually measure blood glucose and calculate insulin dosing using traditional multiple dose injection (MDI) therapy, a burdensome process that puts them at risk for both hypo- and hyp...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Source Type: blogs
The multiple endocrine functions of bone other than those related to mineral metabolism, such as regulation of insulin sensitivity, glucose homeostasis, and energy metabolism, have recently been discovered. In vitro and murine studies investigated the impact of several molecules derived from osteoblasts and osteocytes on glucose metabolism. In addition, the effect of glucose on bone cells suggested a mutual cross-talk between bone and glucose homeostasis. In humans, these mechanisms are the pivotal determinant of the skeletal fragility associated with both type 1 and type 2 diabetes. Metabolic abnormalities associated with...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Authors: Yap YA, Mariño E Abstract Diet-microbiota related inflammatory conditions such as obesity, autoimmune type 1 diabetes (T1D), type 2 diabetes (T2D), cardiovascular disease (CVD) and gut infections have become a stigma in Western societies and developing nations. This book chapter examines the most relevant pre-clinical and clinical studies about diet-gut microbiota approaches as an alternative therapy for diabetes. We also discuss what we and others have extensively investigated- the power of dietary short-chain fatty acids (SCFAs) technology that naturally targets the gut microbiota as an alternativ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
This article is a review of the aging literature in T1D and identifies existing gaps while serving as a call to the research community.Recent FindingsRecent studies have identified an association between cognitive impairment and glycemic variability, as well as increased risk and frequency of hypoglycemia in older adults with T1D. However, limited research exists about additional physical and mental health conditions and barrier to successful treatment in this population.SummaryOlder adults may experience both age- and diabetes-related barriers to diabetes management. Due to the scarcity of aging T1D research, current trea...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
Pulmonary tuberculosis (PTB), caused by Mycobacterium tuberculosis (Mtb), is a major health problem worldwide, further aggravated by the convergence of type 2 diabetes mellitus (DM) which constitutes an important risk factor for TB development. The worse scenario of patients with PTB and DM may be partly related to a more unbalanced defensive response. As such, newly diagnosed PTB patients with DM (TB+DM, n = 11) or not (TB, n = 21), as well as DM (n = 18) patients and pair matched controls (Co, n = 22), were investigated for the circulating immuno-endocrine-metabolic profile (ELISA), along with studies in peripheral blood...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent coupled glucose and sodium reabsorption in the proximal tubule. This leads to glucosuria and lowering of plasma glucose concentrations in people with type 1 diabetes (T1D) and type 2 diabetes (T2D). Additional beneficial effects of SGLT2 inhibitors include reductions in body weight, blood pressure, and plasma uric acid concentrations.1,2 In people with T2D with and without diabetic kidney disease, SGLT2 inhibition improves hard renal outcomes in large-scale clinical trials.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Editorial Source Type: research
ConclusionsThe incidence of severe hypoglycemia was prospectively determined and the association between severe hypoglycemia and higher serum adiponectin was observed in Japanese patients with type 1 and insulin ‐treated type 2 diabetes.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Health